WO2016004216A3 - Hydrogels for treating and ameliorating infections and methods of making and using them - Google Patents

Hydrogels for treating and ameliorating infections and methods of making and using them Download PDF

Info

Publication number
WO2016004216A3
WO2016004216A3 PCT/US2015/038852 US2015038852W WO2016004216A3 WO 2016004216 A3 WO2016004216 A3 WO 2016004216A3 US 2015038852 W US2015038852 W US 2015038852W WO 2016004216 A3 WO2016004216 A3 WO 2016004216A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
kits
manufacture
products
alternative embodiments
Prior art date
Application number
PCT/US2015/038852
Other languages
French (fr)
Other versions
WO2016004216A2 (en
Inventor
John Maki
Newell Bascomb
Fredric Young
Eun Seok GILL
Original Assignee
Vicus Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicus Therapeutics, Llc filed Critical Vicus Therapeutics, Llc
Publication of WO2016004216A2 publication Critical patent/WO2016004216A2/en
Publication of WO2016004216A3 publication Critical patent/WO2016004216A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

In alternative embodiments, the invention provides pharmaceutical compositions, formulations, kits and other products of manufacture, and methods, for treating, ameliorating (e.g., reducing the severity of, slowing the progress of) or preventing infections, comprising local administration of drugs via a hydrogel component or material, wherein optionally amount or concentration of drugs in the hydrogel component or material is a "very high" or an "ultra-high" dose of drugs. In alternative embodiments, the products of manufacture, devices, kits, and compositions, and methods as provided herein are antimicrobial and target infections caused, e.g., by multiple drug resistance organisms (MDROs), or a methicillin-resistant Staphylococcus aureus (MRSAs), or a biofilm. In alternative embodiments, skin, skin structure or bone infections are treated, ameliorated or prevented by products of manufacture, devices, kits, and compositions, and methods as provided herein.
PCT/US2015/038852 2014-07-01 2015-07-01 Hydrogels for treating and ameliorating infections and methods of making and using them WO2016004216A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019812P 2014-07-01 2014-07-01
US62/019,812 2014-07-01

Publications (2)

Publication Number Publication Date
WO2016004216A2 WO2016004216A2 (en) 2016-01-07
WO2016004216A3 true WO2016004216A3 (en) 2016-03-24

Family

ID=55020095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/038852 WO2016004216A2 (en) 2014-07-01 2015-07-01 Hydrogels for treating and ameliorating infections and methods of making and using them

Country Status (1)

Country Link
WO (1) WO2016004216A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220356210A1 (en) * 2019-07-22 2022-11-10 Agency For Science, Technology And Research A series of injectable hydrogels self-assembled from short peptides for various biomedical applications
AU2021324962A1 (en) * 2020-08-10 2023-03-02 Gel4Med, Inc. Self-assembling amphiphilic peptide hydrogels
CN112898607B (en) * 2021-02-23 2022-10-14 中国科学院深圳先进技术研究院 Antibacterial sodium alginate tissue engineering scaffold and preparation method and application thereof
CN115227817A (en) * 2022-06-17 2022-10-25 浙江大学 Laser-driven BBR @ SP bioactive hydrogel, and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050430A1 (en) * 2006-05-05 2008-02-28 Flanner Henry H Pharmaceutical compositions and methods for improved bacterial eradication
US20090162437A1 (en) * 2006-09-26 2009-06-25 Massachusetts Institute Of Technology Modified self-assembling peptides
US20100311640A1 (en) * 2003-06-25 2010-12-09 Massachusetts Institute Of Technology Self-assembling peptide incorporating modifications and methods of use thereof
US20130281547A1 (en) * 2004-07-06 2013-10-24 3D Matrix, Inc. Purified Amphiphilic Peptide Compositions and Uses Thereof
US20130296239A1 (en) * 2007-12-05 2013-11-07 3-D Matrix, Ltd. Material for Wound Healing and Skin Reconstruction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311640A1 (en) * 2003-06-25 2010-12-09 Massachusetts Institute Of Technology Self-assembling peptide incorporating modifications and methods of use thereof
US20130281547A1 (en) * 2004-07-06 2013-10-24 3D Matrix, Inc. Purified Amphiphilic Peptide Compositions and Uses Thereof
US20080050430A1 (en) * 2006-05-05 2008-02-28 Flanner Henry H Pharmaceutical compositions and methods for improved bacterial eradication
US20090162437A1 (en) * 2006-09-26 2009-06-25 Massachusetts Institute Of Technology Modified self-assembling peptides
US20130296239A1 (en) * 2007-12-05 2013-11-07 3-D Matrix, Ltd. Material for Wound Healing and Skin Reconstruction

Also Published As

Publication number Publication date
WO2016004216A2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
EP3895717A4 (en) Pharmaceutical composition for preventing or treating cancer, comprising weissella cibaria wikim28 as active ingredient
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
EP4218823A3 (en) Novel polymeric hgh prodrugs
WO2016004216A3 (en) Hydrogels for treating and ameliorating infections and methods of making and using them
MX2020001404A (en) Dihydrooxadiazinones.
CO2017007076A2 (en) Indenyl compounds, pharmaceutical compositions and medical uses thereof
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
EP3336100A4 (en) Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient
EP3909597A4 (en) Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
AU2014375577A1 (en) Vitamin D and antibacterial uses of composition thereof
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
EP3566702A4 (en) Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, comprising baicalein as active ingredient
EP3964520A4 (en) Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising same as active ingredient
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
IL268224A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
EP3311817A4 (en) Pharmaceutical composition for preventing and treating dry eye diseases, containing imatinib as active ingredient
PH12018501758A1 (en) Oritavancin formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15815286

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15815286

Country of ref document: EP

Kind code of ref document: A2